SCHEMBL1996290

SCHEMBL1996290

CCC(=O)CN1C(=O)CN(Cc2ccc(-c3ccccc3CN3CCOCC3)cc2)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.42
METAP2 P50579 2/20 0.41
BCL2 P10415 3/20 0.39
PDE10A Q9Y233 2/20 0.39
BCL2L1 Q07817 1/20 0.39
HDAC6 Q9UBN7 2/20 0.39
BAK1 Q16611 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
CYP2A13 Q16696 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
BRD4 O60885 1/20 0.37
ENPP2 Q13822 1/20 0.37
MOK Q9UQ07 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997561 0.87 METAP2 (0.43) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1998382 0.85 METAP2 (0.42) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1998644 0.84 METAP2 (0.43) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL2000635 0.83 METAP2 (0.42) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1998733 0.82 METAP2 (0.40) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1996183 0.82 HRH3 (0.40) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1998519 0.82 CYP2A13 (0.42) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL2001280 0.82 CYP2A13 (0.42) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL1998347 0.82 METAP2 (0.41) DHODHMETAP2BCL2PDE10ABCL2L1
SCHEMBL2001274 0.80 HRH3 (0.38) DHODHMETAP2BCL2PDE10ABCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 DHODH 1578/4885METAP2 3694/4885BCL2 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.